Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SB 207499

Known as: SB-207499 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and inflammatory cells, airway smooth muscle and… Expand
Is this relevant?
Review
2006
Review
2006
Among the allergic disorders we emphasize the inflammatory diseases of the inferior respiratory tract by their incidence… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2002
2002
The PDE4 catalytic machinery comprises, in part, two divalent cations in a binuclear motif. Here we report that PDE4A4 expressed… Expand
Is this relevant?
2002
2002
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… Expand
Is this relevant?
Review
2001
Review
2001
  • M. Giembycz
  • Expert opinion on investigational drugs
  • 2001
  • Corpus ID: 21654297
Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The type 4 cAMP-specific phosphodiesterases (PDE4s) are Mg(2+)-dependent hydrolases that catalyze the hydrolysis of 3', 5'-cAMP… Expand
Is this relevant?
Review
1999
Review
1999
Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1997
1997
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept… Expand
Is this relevant?